BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 25192236)

  • 21. From gestalt to gene: early predictive dysmorphic features of PMM2-CDG.
    Martinez-Monseny A; Cuadras D; Bolasell M; Muchart J; Arjona C; Borregan M; Algrabli A; Montero R; Artuch R; Velázquez-Fragua R; Macaya A; Pérez-Cerdá C; Pérez-Dueñas B; Pérez B; Serrano M;
    J Med Genet; 2019 Apr; 56(4):236-245. PubMed ID: 30464053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypolipidaemia among patients with PMM2-CDG is associated with low circulating PCSK9 levels: a case report followed by observational and experimental studies.
    Chong M; Yoon G; Susan-Resiga D; Chamberland A; Cheillan D; Paré G; Seidah NG
    J Med Genet; 2020 Jan; 57(1):11-17. PubMed ID: 31391289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stroke-Like Episodes and Cerebellar Syndrome in Phosphomannomutase Deficiency (PMM2-CDG): Evidence for Hypoglycosylation-Driven Channelopathy.
    Izquierdo-Serra M; Martínez-Monseny AF; López L; Carrillo-García J; Edo A; Ortigoza-Escobar JD; García Ó; Cancho-Candela R; Carrasco-Marina ML; Gutiérrez-Solana LG; Cuadras D; Muchart J; Montero R; Artuch R; Pérez-Cerdá C; Pérez B; Pérez-Dueñas B; Macaya A; Fernández-Fernández JM; Serrano M
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29470411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Congenital disorder of glycosylation type Ia (CDG Ia) - underdiagnosed entity?].
    Sätilä H; Kuusela AL; Pietilä K; Niinikoski H; Keskinen P
    Duodecim; 2016; 132(3):253-9. PubMed ID: 26951030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Yeast Models of Phosphomannomutase 2 Deficiency, a Congenital Disorder of Glycosylation.
    Lao JP; DiPrimio N; Prangley M; Sam FS; Mast JD; Perlstein EO
    G3 (Bethesda); 2019 Feb; 9(2):413-423. PubMed ID: 30530630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurological presentation of a congenital disorder of glycosylation CDG-Ia: implications for diagnosis and genetic counseling.
    Drouin-Garraud V; Belgrand M; Grünewald S; Seta N; Dacher JN; Hénocq A; Matthijs G; Cormier-Daire V; Frébourg T; Saugier-Veber P
    Am J Med Genet; 2001 Jun; 101(1):46-9. PubMed ID: 11343337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unsuccessful intravenous D-mannose treatment in PMM2-CDG.
    Grünert SC; Marquardt T; Lausch E; Fuchs H; Thiel C; Sutter M; Schumann A; Hannibal L; Spiekerkoetter U
    Orphanet J Rare Dis; 2019 Oct; 14(1):231. PubMed ID: 31640729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and molecular diagnosis of non-phosphomannomutase 2 N-linked congenital disorders of glycosylation in Spain.
    Medrano C; Vega A; Navarrete R; Ecay MJ; Calvo R; Pascual SI; Ruiz-Pons M; Toledo L; García-Jiménez I; Arroyo I; Campo A; Couce ML; Domingo-Jiménez MR; García-Silva MT; González-Gutiérrez-Solana L; Hierro L; Martín-Hernández E; Martínez-Pardo M; Roldán S; Tomás M; Cabrera JC; Mártinez-Bugallo F; Martín-Viota L; Vitoria-Miñana I; Lefeber DJ; Girós ML; Serrano Gimare M; Ugarte M; Pérez B; Pérez-Cerdá C
    Clin Genet; 2019 May; 95(5):615-626. PubMed ID: 30653653
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PMM2-CDG: phenotype and genotype in four affected family members.
    Bortot B; Cosentini D; Faletra F; Biffi S; De Martino E; Carrozzi M; Severini GM
    Gene; 2013 Dec; 531(2):506-9. PubMed ID: 23988505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurological manifestations in PMM2-congenital disorders of glycosylation (PMM2-CDG): Insights into clinico-radiological characteristics, recommendations for follow-up, and future directions.
    Muthusamy K; Perez-Ortiz JM; Ligezka AN; Altassan R; Johnsen C; Schultz MJ; Patterson MC; Morava E
    Genet Med; 2024 Feb; 26(2):101027. PubMed ID: 37955240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New and potential strategies for the treatment of PMM2-CDG.
    Gámez A; Serrano M; Gallego D; Vilas A; Pérez B
    Biochim Biophys Acta Gen Subj; 2020 Nov; 1864(11):129686. PubMed ID: 32712172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural Killer Cell Receptors and Cytotoxic Activity in Phosphomannomutase 2 Deficiency (PMM2-CDG).
    García-López R; de la Morena-Barrio ME; Alsina L; Pérez-Dueñas B; Jaeken J; Serrano M; Casado M; Hernández-Caselles T
    PLoS One; 2016; 11(7):e0158863. PubMed ID: 27415628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A mouse model of a human congenital disorder of glycosylation caused by loss of PMM2.
    Chan B; Clasquin M; Smolen GA; Histen G; Powe J; Chen Y; Lin Z; Lu C; Liu Y; Cang Y; Yan Z; Xia Y; Thompson R; Singleton C; Dorsch M; Silverman L; Su SM; Freeze HH; Jin S
    Hum Mol Genet; 2016 Jun; 25(11):2182-2193. PubMed ID: 27053713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of Cell Models to Study Monocyte Functions in PMM2 Congenital Disorders of Glycosylation.
    de Haas P; de Jonge MI; Koenen HJPM; Joosten B; Janssen MCH; de Boer L; Hendriks WJAJ; Lefeber DJ; Cambi A
    Front Immunol; 2022; 13():869031. PubMed ID: 35603178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Novel N-Tetrasaccharide in Patients with Congenital Disorders of Glycosylation, Including Asparagine-Linked Glycosylation Protein 1, Phosphomannomutase 2, and Mannose Phosphate Isomerase Deficiencies.
    Zhang W; James PM; Ng BG; Li X; Xia B; Rong J; Asif G; Raymond K; Jones MA; Hegde M; Ju T; Cummings RD; Clarkson K; Wood T; Boerkoel CF; Freeze HH; He M
    Clin Chem; 2016 Jan; 62(1):208-17. PubMed ID: 26430078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synaptic roles for phosphomannomutase type 2 in a new Drosophila congenital disorder of glycosylation disease model.
    Parkinson WM; Dookwah M; Dear ML; Gatto CL; Aoki K; Tiemeyer M; Broadie K
    Dis Model Mech; 2016 May; 9(5):513-27. PubMed ID: 26940433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mannose supplementation in PMM2-CDG.
    Taday R; Park JH; Grüneberg M; DuChesne I; Reunert J; Marquardt T
    Orphanet J Rare Dis; 2021 Aug; 16(1):359. PubMed ID: 34380532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retinal characteristics of the congenital disorder of glycosylation PMM2-CDG.
    Thompson DA; Lyons RJ; Russell-Eggitt I; Liasis A; Jägle H; Grünewald S
    J Inherit Metab Dis; 2013 Nov; 36(6):1039-47. PubMed ID: 23430200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liposome-encapsulated mannose-1-phosphate therapy improves global N-glycosylation in different congenital disorders of glycosylation.
    Budhraja R; Radenkovic S; Jain A; Muffels IJJ; Ismaili MHA; Kozicz T; Pandey A; Morava E
    Mol Genet Metab; 2024 Jun; 142(2):108487. PubMed ID: 38733638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liver transplantation recovers hepatic N-glycosylation with persistent IgG glycosylation abnormalities: Three-year follow-up in a patient with phosphomannomutase-2-congenital disorder of glycosylation.
    Tahata S; Weckwerth J; Ligezka A; He M; Lee HE; Heimbach J; Ibrahim SH; Kozicz T; Furuya K; Morava E
    Mol Genet Metab; 2023 Apr; 138(4):107559. PubMed ID: 36965289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.